BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 6247888)

  • 1. Evaluation of prostaglandin and prostacyclin antagonism at platelet receptors by aggregometry.
    Eggerman TL; Harker LA; Andersen NH; Wilson CH
    Adv Prostaglandin Thromboxane Res; 1980; 6():389-93. PubMed ID: 6247888
    [No Abstract]   [Full Text] [Related]  

  • 2. Receptors and receptor mechanisms of endogenous platelet stimulatory and inhibitory mediators.
    MacIntyre DE; Bushfield M; MacMillan LJ; Moffat KJ; Murdoch FA; Thomson A; Rossi AG; McNicol A
    Agents Actions Suppl; 1986; 20():45-62. PubMed ID: 3028106
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostaglandins E1 and E2, but neither prostacyclin nor prostaglandin D2 have anti-aggregating activity in chicken blood.
    Bult H; Wechsung E; Houvenaghel A; Herman AG
    Arch Int Pharmacodyn Ther; 1981 Feb; 249(2):306-8. PubMed ID: 7013724
    [No Abstract]   [Full Text] [Related]  

  • 4. The antagonism of prostaglandins I2, E1 and D2 by prostaglandin E2 in human platelets.
    Bonne C; Martin B; Watada M; Regnault F
    Thromb Res; 1981 Jan 1-15; 21(1-2):13-22. PubMed ID: 6262942
    [No Abstract]   [Full Text] [Related]  

  • 5. Biochemical and pharmacological evaluation of thromboxane synthetase inhibitors.
    Gorman RR
    Adv Prostaglandin Thromboxane Res; 1980; 6():417-25. PubMed ID: 6247892
    [No Abstract]   [Full Text] [Related]  

  • 6. On the multiplicity of platelet prostaglandin receptors. I. Evaluation of competitive antagonism by aggregometry.
    Andersen NH; Eggerman TL; Harker LA; Wilson CH; De B
    Prostaglandins; 1980 May; 19(5):711-35. PubMed ID: 6252573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discrimination between platelet prostaglandin receptors with a specific antagonist of bisenoic prostaglandins.
    MacIntyre DE; Gordon JL
    Thromb Res; 1977 Dec; 11(6):705-13. PubMed ID: 203057
    [No Abstract]   [Full Text] [Related]  

  • 8. Evidence for distinct prostaglandin I2 and D2 receptors in human platelets.
    Miller OV; Gorman RR
    J Pharmacol Exp Ther; 1979 Jul; 210(1):134-40. PubMed ID: 221643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the platelet prostaglandin D2 receptor. Loss of prostaglandin D2 receptors in platelets of patients with myeloproliferative disorders.
    Cooper B; Ahern D
    J Clin Invest; 1979 Aug; 64(2):586-90. PubMed ID: 222813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influences of prostaglandins on electrophoretic mobility and aggregation of rabbit platelets.
    Takano S; Itagaki S; Sakurai K; Suzuki T
    Prostaglandins; 1980 Sep; 20(3):579-86. PubMed ID: 6999547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refractoriness of platelets to prostaglandins after infusion in rabbits.
    Bertelé V; Stemerman M; Schafer A; Adelman B; Smith M; Fuhro R; Salzman E
    J Lab Clin Med; 1985 Nov; 106(5):551-61. PubMed ID: 2997353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective antagonism of prostaglandin (PG) E1, PGD2 and prostacyclin (PGI2) on human and rabbit platelets by di-4-phloretin phosphate (DPP).
    Westwick J; Webb H
    Thromb Res; 1978 Jun; 12(6):973-8. PubMed ID: 358484
    [No Abstract]   [Full Text] [Related]  

  • 13. Heparin opposes prostanoid and non-prostanoid platelet inhibitors by direct enhancement of aggregation.
    MacIntyre DE; Handin RI; Rosenberg R; Salzman EW
    Thromb Res; 1981 Apr 1-15; 22(1-2):167-75. PubMed ID: 6270842
    [No Abstract]   [Full Text] [Related]  

  • 14. Heparin does not interfere with prostacyclin and prostaglandin D2 binding to platelets.
    Fortini A; Modesti PA; Abbate R; Gensini GF; Neri Serneri GG
    Thromb Res; 1985 Nov; 40(3):319-28. PubMed ID: 3001968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specificity between the anti-aggregatory actions of prostacyclin, prostaglandin E1 and D2 on platelets.
    Whittle BJ; Hamid S; Lidbury P; Rosam AC
    Adv Exp Med Biol; 1985; 192():109-25. PubMed ID: 2871707
    [No Abstract]   [Full Text] [Related]  

  • 16. The antiaggregatory effectiveness of PGI2 and its binding to specific platelet receptors. A comparative study.
    Jaschonek K; Renn W; Weisenberger H
    Prog Clin Biol Res; 1987; 242():13-8. PubMed ID: 3313410
    [No Abstract]   [Full Text] [Related]  

  • 17. Prostacyclin-sensitive adenylate cyclase and prostacyclin binding sites in platelets and smooth muscle cells.
    Nicosia S; Oliva D; Bernini F; Fumagalli R
    Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 17():593-9. PubMed ID: 6328938
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of prostaglandin I2 and analogs on platelet aggregation and smooth muscle contraction.
    Crane BH; Maish TL; Maddox YT; Corey EJ; Székely I; Ramwell PW
    J Pharmacol Exp Ther; 1978 Jul; 206(1):132-8. PubMed ID: 351171
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of prostacyclin (PGT2) on platelet behaviour. Thrombus formation in vivo and bleeding time.
    Ubatuba FB; Moncada S; Vane JR
    Thromb Haemost; 1979 Apr; 41(2):425-35. PubMed ID: 382434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin receptors on human platelets. Structure-activity relationships of stimulatory prostaglandins.
    MacIntyre DE; Salzman EW; Gordon JL
    Biochem J; 1978 Sep; 174(3):921-9. PubMed ID: 215124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.